Diasome Pharmaceuticals
Diasome is a biotech company focused on advancing liver-targeted metabolic therapies for diabetes, obesity, and metabolic diseases. Their innovative HDV™ platform enables precise delivery of drugs to the portal-hepatic region, aiming to improve efficacy and reduce side effects of treatments. Since 2012, they have been dedicated to translating scientific discovery into real-world patient impact, with a pipeline of therapies targeting insulin, serotonin, and incretins to address unmet needs in metabolic health.
Industries
Nr. of Employees
small (1-50)
Diasome Pharmaceuticals
Products
Liver-targeted rapid-acting mealtime insulin (injectable, Phase 2b)
A subcutaneous rapid-acting insulin candidate formulated on a hepatocyte-directed lipid nanoparticle designed to direct insulin to the liver to restore physiologic mealtime glucose regulation and reduce hypoglycemia risk.
Oral hepatocyte-directed serotonin replacement (preclinical)
An oral small-molecule/peptidic candidate delivered via hepatocyte-directed nanoparticles intended to restore portal-hepatic serotonin levels to improve hepatic insulin utilization and address insulin resistance.
Hepatocyte-directed GLP-1 incretin programs (preclinical)
Injectable and formulation-adapted incretin candidates (GLP-1 and GLP-1/GIP) using hepatocyte-directed nanoparticles to target the gut-liver-brain axis for metabolic endpoints.
HDV™-Insulin
A hepatocyte-directed vesicle insulin lispro formulation that maintains glycemic control while reducing hypoglycemia in adults with type 1 diabetes by preferentially directing insulin to hepatocyte receptors to restore physiologic hepatic insulin exposure.
HDV Lispro
Injectable hepatocyte directed vesicle (HDV) technology added to mealtime insulin Lispro to prevent hypoglycemia in people with type 1 diabetes.
HDV-GLP-1
A hepatocyte-directed vesicle (HDV) targeted GLP-1 therapy designed to access the Gut-Liver-Brain axis, improving efficacy in fat, glucose, and weight endpoints while mitigating off-target side effects.
Liver-targeted rapid-acting mealtime insulin (injectable, Phase 2b)
A subcutaneous rapid-acting insulin candidate formulated on a hepatocyte-directed lipid nanoparticle designed to direct insulin to the liver to restore physiologic mealtime glucose regulation and reduce hypoglycemia risk.
Oral hepatocyte-directed serotonin replacement (preclinical)
An oral small-molecule/peptidic candidate delivered via hepatocyte-directed nanoparticles intended to restore portal-hepatic serotonin levels to improve hepatic insulin utilization and address insulin resistance.
Hepatocyte-directed GLP-1 incretin programs (preclinical)
Injectable and formulation-adapted incretin candidates (GLP-1 and GLP-1/GIP) using hepatocyte-directed nanoparticles to target the gut-liver-brain axis for metabolic endpoints.
HDV™-Insulin
A hepatocyte-directed vesicle insulin lispro formulation that maintains glycemic control while reducing hypoglycemia in adults with type 1 diabetes by preferentially directing insulin to hepatocyte receptors to restore physiologic hepatic insulin exposure.
HDV Lispro
Injectable hepatocyte directed vesicle (HDV) technology added to mealtime insulin Lispro to prevent hypoglycemia in people with type 1 diabetes.
HDV-GLP-1
A hepatocyte-directed vesicle (HDV) targeted GLP-1 therapy designed to access the Gut-Liver-Brain axis, improving efficacy in fat, glucose, and weight endpoints while mitigating off-target side effects.
Expertise Areas
- Hepatocyte-targeted drug delivery
- Lipid nanoparticle formulation
- Oral and injectable formulation development
- Preclinical pharmacology and toxicology
Key Technologies
- Disc-shaped lipid nanoparticles
- Surface ligand-mediated hepatic targeting
- High-capacity payload loading
- Oral formulation technology